12:00 AM
Aug 21, 2006
 |  BC Week In Review  |  Clinical News  |  Clinical Results

RP101: Interim Phase I data

Interim data from an open-label Phase I trial in 22 patients showed that RP101 plus gemcitabine led to survival rates of 68% and 39%...

Read the full 98 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >